ZENNA BELL: Open Payments
NPI 1639668221 · BLOOMFIELD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,481 in 32 payments from 10 companies in 2025. Trend: 2023 $768 · 2024 $42 · 2025 $1,481
Food & beverage: $1,481
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 14 | $327 |
| Otsuka America Pharmaceutical, Inc. | 2 | $247 |
| E.R. Squibb & Sons, L.L.C. | 4 | $210 |
| ABBVIE INC. | 4 | $190 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $148 |
| Collegium Pharmaceutical, Inc. | 1 | $125 |
| Axsome Therapeutics, Inc. | 1 | $122 |
| Lundbeck LLC | 2 | $55 |
| Lilly USA, LLC | 1 | $30 |
| Neurocrine BioSciences, Inc. | 1 | $27 |
Products named: REXULTI, COBENFY, UZEDY, VRAYLAR, CAPLYTA, AUSTEDO XR, Jornay PM, Auvelity.
Industry payments across CT — which companies pay providers there.
